<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783224</url>
  </required_header>
  <id_info>
    <org_study_id>P04512</org_study_id>
    <nct_id>NCT00783224</nct_id>
  </id_info>
  <brief_title>A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)</brief_title>
  <official_title>Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to see if mometasone nasal spray is efficaceous for the treatment of
      perennial allergic rhinitis. Patients will be randomized to active mometasone, placebo
      mometasone, active fluticasone, or placebo fluticasone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 4 Nasal Symptom Score (Sneezing Attack, Rhinorrhea, Nasal Congestion, and Nasal Itching) After 2 Weeks</measure>
    <time_frame>Baseline to 2 weeks of treatment</time_frame>
    <description>The nasal symptoms (sneezing attacks, rhinorrhea, nasal congestion and itching) were rated in 4 grades (+++: 3 points, ++: 2 points, +: 1 point, -: 0 point) based on the evaluation criteria for nasal symptoms. Total possible best score is 0 points, total possible worst score is 12 points.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">351</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Mometasone Furoate Placebo (PLAMF)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone Propionate Placebo (PLAFP)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone Furoate (MF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mometasone furoate nasal spray 200 μg/day(QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone Propionate (FP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for MF</intervention_name>
    <description>Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks</description>
    <arm_group_label>Mometasone Furoate Placebo (PLAMF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for FP</intervention_name>
    <description>Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks</description>
    <arm_group_label>Fluticasone Propionate Placebo (PLAFP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone</intervention_name>
    <description>Mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks</description>
    <arm_group_label>Mometasone Furoate (MF)</arm_group_label>
    <other_name>SCH 032088</other_name>
    <other_name>Nasonex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone</intervention_name>
    <description>Fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks</description>
    <arm_group_label>Fluticasone Propionate (FP)</arm_group_label>
    <other_name>Flonase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with perennial allergic rhinitis meeting all of the followings.

          -  Patients with symptoms of perennial allergic rhinitis, the severity of which is
             moderate or severer according to the severity grading provided in the &quot;Guidelines for
             the Management of Allergic Rhinitis in Japan&quot; (partly modified) with the 4-nasal
             symptom score of 4 or over at informed consent and during the pre-treatment
             observation period

          -  Patients with positive reaction to the eosinophil count in nasal discharge or nasal
             challenge test in addition to the skin test or specific IgE antibody test

          -  Outpatients aged 16 years or over at informed consent

          -  Patients in either sex

          -  Patients (or their legal representatives in case of patients aged under 20 years)
             capable of giving written informed consent

          -  Patients capable of recording nasal allergy diary every day

        Exclusion Criteria:

          -  Patients with a complication of tuberculous diseases or lower respiratory tract
             infections, and those with a complication of otorhinolaryngeal infections(acute upper
             respiratory tract inflammation, acute laryngopharyngitis, acute tonsillitis, etc.)
             requiring treatments judged by the investigator (subinvestigator) at the time of
             enrollment to randomization

          -  Patients with a complication of infection or systemic mycosis for which no effective
             antibiotics are available

          -  Patients with a complication of recurrent epistaxis

          -  Patients with uncured nasal septal ulcer, operated nose or nasal trauma.

          -  Patients with a history of hypersensitivity to steroids and any ingredients of the
             study drugs

          -  Pregnant, lactating or possibly pregnant patients or the patients who themselves or
             whose partners wish to become pregnant during the study

          -  Patients with severe hepatic or renal disorder, heart or blood disease, diabetes
             mellitus, hypertension, or other serious complication, suffering from problems with
             systemic condition

          -  Patients who have pollens as multiple allergens and the period from 7 days before
             enrollment to randomization to completion of the treatment period coincides with the
             period of scattering of relevant pollens

          -  Patients with a complication of vasomotor rhinitis or eosinophilic rhinitis

          -  Patients with a complication of a nasal disease (infectious sinusitis, hypertrophic
             rhinitis, acute or chronic rhinitis, nasal polyps, or septal deviation) which may
             interfere with efficacy evaluation of the study drugs

          -  Patients with a complication of a disease (acute upper respiratory tract inflammation,
             acute laryngitis or acute tonsillitis, etc.) of severity affecting nasal symptoms
             within 7 days before enrollment

          -  Patients who have previously received MF nasal spray

          -  Patients who used FP nasal spray within 28 days before initiation of the pre-treatment
             observation period (7 days before enrollment to randomization)

          -  Patients who have participated in clinical trials of other investigational product(s)
             within 120 days (4 months) before obtaining informed consent or participating at
             present

          -  Patients in whom prior medication expected to be effective for allergic rhinitis was
             not drawn long enough before initiation of treatment with the investigational product
             or the preceding medication cannot be withdrawn

          -  Patients who are being treated with specific desensitization therapy or nonspecific
             allassotherapy or in whom such the therapy was withdrawn within 90 days (3 months)
             before obtaining informed consent (except for patients receiving the maintenance
             therapy at present in whom the therapy began more than 180 days (6 months) before
             obtaining the informed consent)

          -  Other patients whom the investigator or the subinvestigator judged to be inappropriate
             for participation in the present study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>N. Sou et. al; Allergology &amp; Immunology 16(3) page 394-413, (2009.02) -Japanese language journal</citation>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <results_first_submitted>April 15, 2010</results_first_submitted>
  <results_first_submitted_qc>June 9, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2010</results_first_posted>
  <last_update_submitted>May 4, 2015</last_update_submitted>
  <last_update_submitted_qc>May 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mometasone Furoate Placebo (PLAMF)</title>
          <description>Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray</description>
        </group>
        <group group_id="P2">
          <title>Fluticasone Propionate Placebo (PLAFP)</title>
          <description>Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray</description>
        </group>
        <group group_id="P3">
          <title>Mometasone Furoate (MF)</title>
          <description>Mometasone furoate nasal spray 200 μg/day(QD)</description>
        </group>
        <group group_id="P4">
          <title>Fluticasone Propionate (FP)</title>
          <description>Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="143"/>
                <participants group_id="P4" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="142"/>
                <participants group_id="P4" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discarded the Investigational Drug Used</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate as a study subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mometasone Furoate Placebo (PLAMF)</title>
          <description>Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray</description>
        </group>
        <group group_id="B2">
          <title>Fluticasone Propionate Placebo (PLAFP)</title>
          <description>Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray</description>
        </group>
        <group group_id="B3">
          <title>Mometasone Furoate (MF)</title>
          <description>Mometasone furoate nasal spray 200 μg/day(QD)</description>
        </group>
        <group group_id="B4">
          <title>Fluticasone Propionate (FP)</title>
          <description>Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="143"/>
            <count group_id="B4" value="142"/>
            <count group_id="B5" value="351"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;20 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20-29 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-59 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=60 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in 4 Nasal Symptom Score (Sneezing Attack, Rhinorrhea, Nasal Congestion, and Nasal Itching) After 2 Weeks</title>
        <description>The nasal symptoms (sneezing attacks, rhinorrhea, nasal congestion and itching) were rated in 4 grades (+++: 3 points, ++: 2 points, +: 1 point, -: 0 point) based on the evaluation criteria for nasal symptoms. Total possible best score is 0 points, total possible worst score is 12 points.</description>
        <time_frame>Baseline to 2 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate Placebo (PLAMF)</title>
            <description>Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate Placebo (PLAFP)</title>
            <description>Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray</description>
          </group>
          <group group_id="O3">
            <title>Mometasone Furoate (MF)</title>
            <description>Mometasone furoate nasal spray 200 μg/day(QD)</description>
          </group>
          <group group_id="O4">
            <title>Fluticasone Propionate (FP)</title>
            <description>Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 4 Nasal Symptom Score (Sneezing Attack, Rhinorrhea, Nasal Congestion, and Nasal Itching) After 2 Weeks</title>
          <description>The nasal symptoms (sneezing attacks, rhinorrhea, nasal congestion and itching) were rated in 4 grades (+++: 3 points, ++: 2 points, +: 1 point, -: 0 point) based on the evaluation criteria for nasal symptoms. Total possible best score is 0 points, total possible worst score is 12 points.</description>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="143"/>
                <count group_id="O4" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.84" spread="0.25"/>
                    <measurement group_id="O2" value="8.41" spread="0.29"/>
                    <measurement group_id="O3" value="8.27" spread="0.15"/>
                    <measurement group_id="O4" value="8.29" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.37"/>
                    <measurement group_id="O2" value="1.74" spread="0.35"/>
                    <measurement group_id="O3" value="3.90" spread="0.17"/>
                    <measurement group_id="O4" value="3.69" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mometasone Furoate Placebo and Fluticasone Propionate Placebo</title>
          <description>Both placebo groups (arms) were combined to report adverse events</description>
        </group>
        <group group_id="E2">
          <title>Mometasone Furoate (MF)</title>
          <description>Mometasone furoate nasal spray 200 μg/day(QD)</description>
        </group>
        <group group_id="E3">
          <title>Fluticasone Propionate (FP)</title>
          <description>Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wisdom Teeth Removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="143"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Inflammation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="143"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only restriction on the PI is that the PI needs to get approval from the sponsor for publication of the trial results prior to public release.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck, Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

